Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular &amp; Electrodiagnostic Medicine Annual Meeting.

Medicine

Health & Fitness

Myasthenia gravis, an autoimmune disease characterized by fluctuating muscle weakness, greatly impacts patients’ functioning and activities of daily living. Important treatment advances continue to be made to reduce patient burden of disease and overcome safety, efficacy, and other limitations of available therapies. Join Nicholas Silvestri, MD, as he reports on research results of some of these advances presented at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.

Share Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT

Sign up to save your podcasts

Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT

Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT